Association of plasma adiponectin and leptin levels with the development and progression of ovarian cancer

Jin, Jing Hui; Kim, Hyun-Jung; Kim, Chan Young; Kim, Yun Hwan; Ju, Woong; Kim, Seung Cheol

doi:10.5468/ogs.2016.59.4.279

Cited by 34 publications

(42 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, it has been reported that elevated insulin levels also lead to a leptin overexpression: increased leptin plasma concentrations are believed to be associated with the occurrence and progression of endometrial and ovarian cancer [13][14][15]. Furthermore, leptin can also upregulate vascular endothelial growth factor (VEGF), a hallmark of malignant tumor development [16].…”

Section: Biological Links Between T2d and Gynecological Cancersmentioning

confidence: 99%

Linking type 2 diabetes and gynecological cancer: an introductory overview

Anastasi

Filardi

Tartaglione

et al. 2018

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

Type 2 diabetes (T2D) is a chronic disease with a growing prevalence and a leading cause of death in many countries. Several epidemiological studies observed an association between T2D and increased risk of many types of cancer, such as gynecologic neoplasms (endometrial, cervical, ovarian and vulvar cancer). Insulin resistance, chronic inflammation and high free ovarian steroid hormones are considered the possible mechanisms behind this complex relationship. A higher risk of endometrial cancer was observed in T2D, even though this association largely attenuated after adjusting for obesity. A clear relationship between the incidence of cervical cancer (CC) and T2D has still not be determined; however T2D might have an impact on prognosis in patients with CC. To date, studies on the association between T2D and ovarian cancer (OC) are limited. The effect of pre-existing diabetes on cancer-specific mortality has been evaluated in several studies, with less clear results. Other epidemiological and experimental studies focused on the potential role of diabetes medications, mainly metformin, in cancer development in women. The correct understanding of the link between T2D and gynecologic cancer risk and mortality is currently imperative to possibly modify screening and diagnostic-therapeutic protocols in the future.

show abstract

Section: Biological Links Between T2d and Gynecological Cancersmentioning

confidence: 99%

Linking type 2 diabetes and gynecological cancer: an introductory overview

Anastasi

Filardi

Tartaglione

et al. 2018

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

show abstract

“…Women with OC often have no typical symptoms until the disease reaches an advanced stage with peritoneal dissemination and massive ascites [2]. Debulking surgery and chemotherapy are currently the most commonly used therapies for OC treatment [3], but the 5-year survival rate of OC patients is only 45% [4]. It is necessary to explore new molecular mechanisms and to identify new potential therapeutic targets to improve OC treatment.…”

mentioning

confidence: 99%

Knockdown of Tripartite Motif Containing 28 suppresses the migration, invasion and epithelial–mesenchymal transition in ovarian carcinoma cells through down-regulation of Wnt/β-catenin signaling pathway

Deng¹,

Zhang²,

Zhang³

et al. 2017

neo

View full text Add to dashboard Cite

Tripartite motif containing 28 (TRIM28) is a transcriptional corepressor of Kruppel-associated box zinc finger protein, which has been reported to participate in carcinogenesis. Nonetheless, whether TRIM28 plays a role in the metastasis of ovarian carcinoma (OC) is unclear and requires further investigation. In this study, two OC cell lines (A2780 and OVCAR-3) with stable low expression of TRIM28 were established via RNA interference. We found that the migratory and invasive ability of TRIM28-silenced OC cells significantly decreased. The expression and activity of matrix metallopeptidase (MMP)-2 and MMP-9 in these OC cells were inhibited. The TRIM28 shRNA also suppressed the epithelial-mesenchymal transition (EMT) of OC cells as evidenced by the up-regulated E-cadherin and the downregulated Vimentin and N-cadherin. Additionally, the Wnt/β-catenin signaling pathway was suppressed in TRIM28-silenced OC cells: the activity of β-catenin was inhibited, the expression of total and nuclear β-catenin, Axin 2, T-cell factor 1 (TCF1) and lymphoid enhancer binding factor 1 (LEF1) were decreased, whereas the phosphorylation of β-catenin at Ser33/37 was enhanced. Further, re-expression of active β-catenin in TRIM28-silenced OC cells partly restored their metastasis in vitro. Taken together, our study demonstrates a contributory role of TRIM28 in OC metastasis in vitro, suggesting TRIM28 as a novel therapeutic target for this malignant tumor.

show abstract

“…There is some evidence that lower levels of leptin [ 44 ] and higher levels of prolactin [ 45 ] might be associated with increased risk of ovarian cancer.…”

Section: Discussionmentioning

confidence: 99%

Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers

et al. 2017

View full text Add to dashboard Cite

BackgroundScreening for ovarian cancer (OC) in women at high risk consists of a combination of carbohydrate antigen 125 (CA125) and transvaginal ultrasound, despite their low sensitivity and specificity. This could be improved by the combination of several biomarkers, which has been shown in average risk patients but has not been investigated until now in female BRCA mutation carriers.MethodsUsing a multiplex, bead-based, immunoassay system, we analyzed the concentrations of leptin, prolactin, osteopontin, insulin-like growth factor II, macrophage inhibitory factor, CA125 and human epididymis antigen 4 in 26 healthy wild type women, 26 healthy BRCA1 mutation carriers, 28 wildtype OC patients and 26 OC patients with BRCA1 mutation.ResultsUsing the ROC analysis, we found a high overall sensitivity of 94.3% in differentiating healthy controls from OC patients with comparable results in the wildtype subgroup (sensitivity 92.8%, AUC = 0.988; p = 5.2e-14) as well as in BRCA1 mutation carriers (sensitivity 95.2%, AUC = 0.978; p = 1.7e-15) at an overall specificity of 92.3%.The used algorithm also allowed to identify healthy BRCA1 mutation carriers when compared to healthy wildtype women (sensitivity 88.4%, specificity 80.7%, AUC = 0.895; p = 6e-08), while this was less pronounced in patients with OC (sensitivity 66.7%, specificity 67.8%, AUC = 0.724; p = 0.00065).ConclusionWe have developed an algorithm, which can differentiate between healthy women and OC patients and have for the first time shown, that such an algorithm can also be used in BRCA mutation carriers. To clarify a suggested benefit to the existing early detection program, large prospective trials with mainly early stage OC cases are warranted.

show abstract

Association of plasma adiponectin and leptin levels with the development and progression of ovarian cancer

Cited by 34 publications

References 31 publications

Linking type 2 diabetes and gynecological cancer: an introductory overview

Linking type 2 diabetes and gynecological cancer: an introductory overview

Knockdown of Tripartite Motif Containing 28 suppresses the migration, invasion and epithelial–mesenchymal transition in ovarian carcinoma cells through down-regulation of Wnt/β-catenin signaling pathway

Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers

Contact Info

Product

Resources

About